Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs. 2016

Chenlin Shen, and Xiaohui Huang, and Jun Li, and Ping Zhang, and Lin Li, and Wei Zhang, and Tingting Hu, and Faustina Pappoe, and Jihan Huang, and Haiqin Tang
a Department of Basic and Clinical Pharmacology , School of Pharmacy, Anhui Medical University , Hefei , Anhui , China .

1. Warfarin and aspirin are widely used in a wide spectrum of thromboembolic and atherothrombotic diseases. Despite the potential efficacy of warfarin-aspirin therapy, the safety and side effect of combined therapy remains unclear. 2. The aim of this study was to investigate the pharmacokinetic and pharmacodynamic interactions between warfarin and aspirin in beagles after single and multiple doses. 3. Coadministration of aspirin had no significant effects on the area under the plasma concentration time curve (AUC(0-t)) and maximum plasma concentration (Cmax) of R- and S-warfarin after a single dose of warfarin, but significantly increase the AUC(0-t) and Cmax and dramatically decrease the clearance (CL) of R- and S-warfarin after multiple dose of warfarin. Accordingly, there was a slight increase in the AUEC(0-t) and Emax of activated partial thromboplastin time (aPTT), prothrombin time (PT) and international normalized ratio (INR) after multiple dose of warfarin. 4. Coadministration of warfarin had no markedly effects on the AUC(0-t) and Cmax of aspirin and its metabolite salicylic acid after single or multiple dose of aspirin. Meanwhile, the AUEC(0-t) and Emax of inhibition of platelet aggregation (IPA) were not significantly affected by warfarin. 5. Our animal study indicated that coadministration of aspirin with warfarin can cause significant pharmacokinetic and pharmacodynamic drug-drug interactions in beagles. However, more studies are urgently needed to assess related information of warfarin-aspirin drug interactions in healthy volunteers or patients.

UI MeSH Term Description Entries
D008297 Male Males
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D012015 Reference Standards A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy. Standard Preparations,Standards, Reference,Preparations, Standard,Standardization,Standards,Preparation, Standard,Reference Standard,Standard Preparation,Standard, Reference
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic

Related Publications

Chenlin Shen, and Xiaohui Huang, and Jun Li, and Ping Zhang, and Lin Li, and Wei Zhang, and Tingting Hu, and Faustina Pappoe, and Jihan Huang, and Haiqin Tang
October 2003, Acta pharmacologica Sinica,
Chenlin Shen, and Xiaohui Huang, and Jun Li, and Ping Zhang, and Lin Li, and Wei Zhang, and Tingting Hu, and Faustina Pappoe, and Jihan Huang, and Haiqin Tang
September 2012, Journal of ethnopharmacology,
Chenlin Shen, and Xiaohui Huang, and Jun Li, and Ping Zhang, and Lin Li, and Wei Zhang, and Tingting Hu, and Faustina Pappoe, and Jihan Huang, and Haiqin Tang
July 2008, The American journal of tropical medicine and hygiene,
Chenlin Shen, and Xiaohui Huang, and Jun Li, and Ping Zhang, and Lin Li, and Wei Zhang, and Tingting Hu, and Faustina Pappoe, and Jihan Huang, and Haiqin Tang
July 2019, Clinical pharmacology in drug development,
Chenlin Shen, and Xiaohui Huang, and Jun Li, and Ping Zhang, and Lin Li, and Wei Zhang, and Tingting Hu, and Faustina Pappoe, and Jihan Huang, and Haiqin Tang
April 1986, Journal of pharmacobio-dynamics,
Chenlin Shen, and Xiaohui Huang, and Jun Li, and Ping Zhang, and Lin Li, and Wei Zhang, and Tingting Hu, and Faustina Pappoe, and Jihan Huang, and Haiqin Tang
May 2010, British journal of clinical pharmacology,
Chenlin Shen, and Xiaohui Huang, and Jun Li, and Ping Zhang, and Lin Li, and Wei Zhang, and Tingting Hu, and Faustina Pappoe, and Jihan Huang, and Haiqin Tang
January 1995, Clinical pharmacokinetics,
Chenlin Shen, and Xiaohui Huang, and Jun Li, and Ping Zhang, and Lin Li, and Wei Zhang, and Tingting Hu, and Faustina Pappoe, and Jihan Huang, and Haiqin Tang
January 2016, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Chenlin Shen, and Xiaohui Huang, and Jun Li, and Ping Zhang, and Lin Li, and Wei Zhang, and Tingting Hu, and Faustina Pappoe, and Jihan Huang, and Haiqin Tang
June 2013, Drugs in R&D,
Chenlin Shen, and Xiaohui Huang, and Jun Li, and Ping Zhang, and Lin Li, and Wei Zhang, and Tingting Hu, and Faustina Pappoe, and Jihan Huang, and Haiqin Tang
January 2017, PloS one,
Copied contents to your clipboard!